General
Preferred name
RAF-265
Synonyms
RAF265 ()
CHIR-265 ()
CHIR-265, NVP-RAF265 ()
RAF 265 ()
RAF265 (CHIR-265) ()
NVP-RAF265 ()
Raf 265 ()
P&D ID
PD003613
CAS
927880-90-8
Tags
available
drug candidate
Drug indication
Melanoma
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION CHIR-265 is an orally bioavailable inhibitor of RAF kinases, including the BRAF V600E mutant. It also inhibits phosphorylation of VEGFR2 (link to this abstract at AACR Meeting Abstracts Online #4876). (GtoPdb)
DESCRIPTION ihibitor of VEGFR2 and BRAF (Informer Set)
DESCRIPTION Potent and selective inhibitor of TGF-betaRI (Tocris Bioactive Compound Library)
DESCRIPTION RAF265 is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. (BOC Sciences Bioactive Compounds)
Cell lines
3
Organisms
1
Compound Sets
23
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Informer Set
LINCS compound set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
518.13
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
5
cLogP
6.93
TPSA
80.65
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.25
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
BRAF
KDR
b-RAF
VEGFR2
Raf
VEGFR
Apoptosis related,Raf,VEGFR
Compound status
clinical
Targets
CRAF,BRAF,KDR
Pathway
Angiogenesis
MAPK
Tyrosine Kinase/Adaptors
Apoptosis
Autophagy
MAPK/ERK Pathway
Protein Tyrosine Kinase/RTK
Primary Target
Raf Kinases
MOA
Inhibitor
RAF inhibitor, VEGFR inhibitor
Source data